EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Comparison of long‐term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia‐positive acute lymphoblastic leukemia: A multicenter retrospective study

Fangshu Guan iD, Luxin Yang, Yi Chen, Jimin Shi, Xiaolu Song, Xiaoyu Lai, Ying Lu, Lizhen Liu, Guifang Ouyang, Yanmin Zhao, Jian Yu, Yang Xu iD und 8 weitere

Cancer · 2024

DOI: 10.1002/cncr.35232 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer, 2024. Verfasst von Fangshu Guan und 19 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Dasatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Hematopoietic Stem Cell Transplantation, Imatinib Mesylate. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although the prognosis of Philadelphia‐positive acute lymphoblastic leukemia (Ph+ ALL) has improved with the introduction of tyrosine kinase inhibitors (TKIs) and stem cell transplantation, prevention of relapse after transplantation remains a concern. The aim of this study was to compare the impact of TKI prophylaxis with imatinib and dasatinib on long‐term outcomes after transplantation.

Methods

Patients with Ph+ ALL who underwent allogeneic hematopoietic stem cell transplantation (allo‐HSCT) at first complete remission (CR1) and received TKI prophylaxis after allo‐HSCT were included in this retrospective analysis. Two cohorts were established based on the choice of TKI prophylaxis: the imatinib (Ima) and dasatinib (Das) cohorts. The survival and safety outcomes of these cohorts were compared.

Results

Ninety‐one patients in the Ima cohort and 50 in the Das cohort were included. After a median follow‐up of 50.6 months, the 5‐year cumulative incidence of relapse, nonrelapse mortality rate, and overall survival in the Ima and Das cohorts were 16.1% and 12.5%, 5.2% and 9.8%, and 86.5% and 77.6%, respectively, with no statistical differences. The cumulative incidence of mild chronic graft‐versus‐host disease was higher in the Das cohort. The most common adverse event was neutropenia (64.7% vs. 69.5%). The Das cohort had a higher incidence of gastrointestinal bleeding (25.5% vs. 2.3%) and gastrointestinal reaction (48.9% vs. 31.4%) than the Ima cohort. The proportion of patients treated on schedule was significantly lower in the Das cohort than in the Ima cohort, and drug intolerance was the main reason for protocol violation.

Conclusions

For patients with Ph+ ALL undergoing allo‐HSCT in CR1, imatinib prophylaxis achieved long‐term outcomes similar to those of dasatinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DasatinibPrecursor Cell Lymphoblastic Leukemia-LymphomaHematopoietic Stem Cell TransplantationImatinib MesylateTransplantation, HomologousProtein Kinase InhibitorsHumansRetrospective StudiesMaleFemaleAdultMiddle AgedYoung AdultAdolescentTreatment OutcomeAntineoplastic AgentsGraft vs Host Disease

Stichwörter der Autor:innen

Philadelphia chromosomeacute lymphoblastic leukemiaallo‐HSCTprophylaxistyrosine kinase inhibitors

Substanzen

DasatinibImatinib MesylateProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
  • Department of Hematology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Cancer Center, Department of Hematology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou, Zhejiang, China.
  • Department of Hematology, the Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China.
  • Department of Hematology, the First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
  • Department of Hematology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.

ORCID-Profile: Fangshu Guan, Yang Xu, Yi Zhao, Xi Qiu, Zhen Cai, He Huang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Guan, F., Yang, L., Chen, Y., Shi, J., Song, X., Lai, X., Lu, Y., Liu, L., Ouyang, G., Zhao, Y., Yu, J., Xu, Y., Lan, J., Fu, H., Zhao, Y., Qiu, X., Zhu, P., Cai, Z., Huang, H., & Luo, Y. (2024). Comparison of long‐term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia‐positive acute lymphoblastic leukemia: A multicenter retrospective study. Cancer. https://doi.org/10.1002/cncr.35232

Vancouver

Guan F, Yang L, Chen Y, Shi J, Song X, Lai X, et al. Comparison of long‐term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia‐positive acute lymphoblastic leukemia: A multicenter retrospective study. Cancer. 2024. doi:10.1002/cncr.35232

BibTeX
@article{Guan2024,
  author = {Guan, Fangshu and Yang, Luxin and Chen, Yi and Shi, Jimin and Song, Xiaolu and Lai, Xiaoyu and Lu, Ying and Liu, Lizhen and Ouyang, Guifang and Zhao, Yanmin and Yu, Jian and Xu, Yang and Lan, Jianping and Fu, Huarui and Zhao, Yi and Qiu, Xi and Zhu, Panpan and Cai, Zhen and Huang, He and Luo, Yi},
  title = {Comparison of long‐term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia‐positive acute lymphoblastic leukemia: A multicenter retrospective study},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.35232}
}
Kostenlos starten →